Acropolis Investment Management LLC Sells 10,253 Shares of Bristol Myers Squibb Company $BMY

Acropolis Investment Management LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 35.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,671 shares of the biopharmaceutical company’s stock after selling 10,253 shares during the period. Acropolis Investment Management LLC’s holdings in Bristol Myers Squibb were worth $1,007,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership lifted its stake in Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after purchasing an additional 9,171,098 shares during the last quarter. Man Group plc boosted its stake in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after purchasing an additional 4,588,601 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Bristol Myers Squibb by 67.8% during the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock valued at $444,682,000 after purchasing an additional 3,982,439 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Bristol Myers Squibb by 393.2% during the 2nd quarter. First Trust Advisors LP now owns 4,592,548 shares of the biopharmaceutical company’s stock worth $212,589,000 after purchasing an additional 3,661,431 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Down 1.4%

Shares of Bristol Myers Squibb stock opened at $58.59 on Friday. The stock’s 50-day moving average is $58.82 and its 200 day moving average is $52.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The firm has a market cap of $119.62 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the firm posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Analysts Set New Price Targets

BMY has been the topic of a number of research analyst reports. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Piper Sandler reissued an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.